156 results about "Immune modulation" patented technology

The present invention relates to Roseburia flagellin, and / or a polynucleotide sequence encoding said Roseburia flagellin, and / or a vector comprising said polynucleotide sequence, and / or a host cell, including bacteria, comprising said vector, and / or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.

Methods, systems, and apparatus for the treatment of heart failure (both systolic and diastolic), hypertension, and arrhythmia in patients by stimulating one or more nerves, particularly peripheral nerves, using neurostimulation are described. The therapeutic treatment is accomplished by applying electrical signals to at least one or more nerves using cutaneous, subcutaneous, implantable, or catheter-based neurostimulation assemblies, alone or in combination with one or more additional therapy or stimulation devices associated with the patient's heart, and / or with one or more therapeutic drug infusions or therapies, such as immune modulation therapy (IMT).

Disclosed are methods, compositions of matter, and protocols useful for the induction of a therapeutic immune modulatory response through administration of exosomes derived from a stem cell source. In one embodiment, said stem cell source is endometrial regenerative cells. Specifically, in one embodiment stem cell derived exosomes are used as a method of treating an autoimmune condition such as rheumatoid arthritis, multiple sclerosis, or systemic lupus erythromatosis.

Disclosed are cells, methods of modulating cells, and therapeutic uses of the cells for the immune modulation of mammals in need thereof. Immune modulation including alteration of cytokine profile, cytotoxic activity, antibody production and inflammatory states is achieved through the administration of various cell types that have been unmanipulated or manipulated in order to endow specific biological activity. Cellular subsets and administration of the subsets in combination with various agents are also provided. One embodiment teaches the previously unknown finding that adipose tissue derived mononuclear cells contain T cells with immune regulatory properties that alone or synergistically with various stem cells induce immune modulation upon administration. Another embodiment is the finding that stimulation of stem cell activation results in stem cell secondary activation of immune modulatory cells, one type which is T regulatory cells (Tregs). One specific embodiment involves extraction of a heterogenous stem cell pool, which contains T regulatory cells, treatment in culture of the population with agents known to stimulate stem cell activation, then subsequent extraction and administration of the purified Tregs. Other embodiments include expansion of Tregs in the presence of antigen in order to generate anti-specific Tregs.

Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.

The present invention relates to CD200 receptor isoforms and modulators thereof and their use in methods of immune modulation and pharmaceutical compositions.

Oligonucleotides containing the non-palindromic sequence motif:X1X2X3X4X5X6X7X8,wherein X1 is C,T,G or A (preferably T or C); wherein X2 is C,T,G or A; wherein X7 is C,T,G or A (preferably G); at least three, and preferably all, of X3, X4, X5, X6 and X8 are T; and with the proviso that, in the motif, a C does not precede a G (in other terms, the nucleic acid motif does not consist of a CpG oligonucleotide), that modulate the immune response of animals of the order Primate, including humans, are disclosed. This immune modulation is characterized by stimulation of proliferation, differentiation, cytokine production and antibody production on B-cells and cell differentiation on plasmacytoid dendritic cells.

The present invention relates to compositions comprising polypeptides and polysaccharides. The compositions are in general immune modulating. The invention also discloses methods of producing these compositions using filamentous fungi cultivated in liquid medium. The compositions are useful for example in the treatment of immune compromised conditions.

The present invention generally relates to compositions and methods for topical or transdermal delivery for immune modulation. In some cases, the composition may include nitric oxide and / or peptides. The nitric oxide and / or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

A method for repairing animal tissue damage due to an inflammatory reaction in an animal has the steps of providing umbilical cord blood cells (UCBCs) in a pharmaceutically acceptable form; and administering a sufficient dose of UCBC at an optimal time thereby reducing the injury from the inflammatory reaction. Also provided are method of treating cerebrovascular accident, acute central nervous inflammation, multiple sclerosis, myocardial ischemia, and neonatal bronchopulmonary distress. For determining the optimal time of UCBCs administration, there is provided a kit containing antibodies for IL-8 and MCP-1.

The present invention is directed to an implantable immune modulation device that is useful for modulating an immune response in mammals, comprising a plurality of fibers, within a porous shell. The fiber filling is loaded with single or multiple antigens, and optionally one or more biologically active compounds such as cytokines (e.g. lymphokines, chemokines etc.), attachment factors, genes, peptides, proteins, nucleotides, carbohydrates or cells depending on the application.

Biologically active peptides that are derived from or are similar to sequences of the alphaS1-, alphaS2-, beta- or kapa-casein fractions of milk casein. These peptides are capable of immune modulation and other therapeutic activities, including but not limited to stimulating and enhancing immune response, protecting against viral infection, normalizing serum cholesterol levels, and stimulating hematopoiesis. The casein-derived peptides are non-toxic and can be used to treat and prevent immune pathologies, diabetes, hypercholesterolemia, hematological disorders and viral-related diseases.

Compositions that include extracts from sources of immune modulators that include nanofraction immune modulator molecules (i.e., molecules having molecular weights of about 3,000 Da and less) are disclosed. These compositions may also include other immune modulators, such as transfer factor. Administration of compositions with extracts that include nanofraction immune modulator molecules modulates the cell-mediated immunity (e.g., down-regulates undesired T cell activity) of a subject to which such compositions are administered. When administered with transfer factor, the combination of nanofraction immune modulator molecules and transfer factor down-regulates undesired T cell activity while increasing, or up-regulating, T cell activity against pathogens and other undesirable entities, such as cancer cells and other aberrant or mutated cells. Assays and assay techniques for evaluating the immune modulation capabilities of various substances are also disclosed.

The present invention relates to methods for the detection and therapy of inflamed tissue, whereby immune modulators are used to increase the uptake of diagnostic or therapeutic compositions by inflammatory cells.

The present invention relates to a kind of active component extracted from glossy ganoderma spore as material and its preparation and use. The glossy ganoderma spore oil contains total triterpene in 24-35 %, has density of 0.88-0.92, refractive index 1.45-1.48 and acid number 14-35. The preparation process with wall breaking glossy ganoderma spore as material includes mixing with alcohol solution, pelletizing, drying, supercritical CO2 extraction in extracting reactor, two-stage separation, and extraction to obtain oily matter, and eccentric separation to obtain yellow oil. The glossy ganoderma spore oil product is used in preparing medicine and food for raising body's immunity. The process of the present invention is simple, stable in product quality, convenient and high in product yield, and is suitable for industrial production.

An attenuated herpes virus which lacks a functional vhs gene or a functional equivalent thereof, but which has a functional UL43 gene or functional equivalent thereof, stimulates an immune response when dendritic cells are infected with the virus.

The present invention relates to methods for the detection and therapy of active atheromatous plaques, and in particular vulnerable plaques, whereby immune modulators are used to increase the uptake of diagnostic or therapeutic compositions by the inflammatory cells associated with such plaques.

The invention relates to the field of protein, and in particular to a bioactive polypeptide SKHSSLDCVL, and a preparation method and application thereof. An amino acid sequence of the bioactive polypeptide SKHSSLDCVL is Ser-Lys-His-Ser-Ser-Leu-Asp-Cys-Val-Leu. An in-vitro antioxidant experiment and an in-vitro immunological function promoting experiment verify that the bioactive polypeptide SKHSSLDCVL has better antioxidant biological activity and a better immune modulating function; on one hand, the bioactive polypeptide SKHSSLDCVL has better antioxidant activity and is capable of removing free radicals in a body and increasing the quality of life; on the other hand, the bioactive polypeptide SKHSSLDCVL is capable of enhancing in-vitro proliferation ability of lymphocytes and macrophages, promoting the ability of swallowing neutral red by the macrophages, increasing the ability of defending external pathogen infection by the body and reducing the morbidity of the body, and has a very important significance in developing food, healthcare products and drugs having an immune modulating function and an antioxidant function.

Methods and apparatus are disclosed co-culturing stem cells with mononuclear cells and / or lymphocytes to modulate their function. The invention also discloses the use of stem cells to educate autoreactive immune cells as a mechanism to treat autoimmune diseases and immune disorder-related diseases, such as diabetes. In one aspect of the invention, bioreactors are disclosed closed for modulating lymphocytes and suppressing autoreactive T cells. The bioreactors can include a chamber having at least one positively charged and / or hydrophobic substrate surface, a population of stem cells attached to the substrate surface, an inlet conduit for introducing lymphocytes into the chamber, and an outlet conduit for extracting treated lymphocytes following co-culturing with the stem cells.

The present invention deals with the production of food products with a health promoting effect, namely immune modulation in general, and lowering and / or stabilizing blood sugar levels. The food products concerned comprise polysaccharides from edible or medicinal mushrooms. These are produced through fermentation instead of conventional cultivation of mushrooms. Fermentation process is preferably done in submerged cultures, especially fed-batch or step-up cultures.

Mitogen induced nuclear orphan receptor (MINOR) is described as inducing apoptosis in dendritic cells (DCs). Downregulation of its expression results in a downregulation of apoptosis. A novel approach of inhibiting DC apoptosis is described employing small interfering RNA (siRNA) that targets MINOR. Improved DC-based vaccines exhibiting longer lifespan of DCs, increased potency of DCs, and enhanced immunogenicity are described.

The invention relates to the field of protein, in particular to a bioactive polypeptide PMIGVNQELAY, and a preparation method and application thereof. The amino acid sequence of the bioactive polypeptide PMIGVNQELAY is Pro-Met-Ile-Gly-Val-Asn-Gln-Glu-Leu-Ala-Tyr. In vitro antioxidant experiments and in vitro immune function promoting experiments prove that the polypeptide PMIGVNQELAY has better antioxidant biological activity and immune modulating functions; on one hand, good antioxidant activity is realized; free radicals in the body can be cleared away; the life quality is improved; on the other hand, the bioactive polypeptide PMIGVNQELAY can enhance the in vitro multiplication capacity of lymphocytes and macrophages; the capability of the macrophages for devouring toluylene red is promoted; the capability of the body for resisting the external pathogen infection is improved; the body morbidity is reduced; very important significance is realized for developing food, health care products and medicines with the immune modulating function and the antioxidant function.

Methods and agents for immune modulation and methods for identifying putative immune modulators are provided.

The present invention describes the use of leptin for the immune modulation of the Th1 / Th2 response. One aspect of the invention provides for a shift in the Th1 / Th2 cell balance towards pro-inflammatory cytokine producing cells. This shift results from an increase in the levels, expression and / or the activity of leptin. Another aspect of the invention provides for a shift in the Th1 / Th2 cell balance towards anti-inflammatory cytokine producing cells. This shift results from a decrease in the levels, expression and / or the activity of leptin. The shifting of the Th1 / Th2 balance provides a method for the treatment of a variety of diseases and disorders.

The invention relates to the therapeutic use of oligonucleotides as immune modulatory agents in immunotherapy applications. More particularly, the invention provides immune modulatory oligonucleotide compositions for use in methods for generating an immune response or for treating a patient in need of immune modulation. The immune modulatory oligonucleotides of the invention preferably comprise novel pyrimidines and purines.

The invention aims to provide a cultivation method for nano-selenium containing Tie Guanying organic tea plant and the nano-selenium containing Tie Guanying organic tea plant. One hundred grams of organic tea leaves obtained through the cultivation method contains 40 to 65 micrograms of nano-selenium with a granular diameter of 50 to 200 nanometers, 4.36 to 5.45 grams of ether extracts and the balance dietary fibers, carbohydrates, proteins, microelements such asmanganese, magnesium, phosphorus, zinc, iron, copper, sodium, calcium and potassium, and vitamins including A, A1, B1, B2, B5, E and renieratene. The organic tea leaves meet standards of Green Organic Tea Certification and requirements and standards of organic tea production, processing and trade. Selenium has functions of free radical removal, prevention of cancers, beauty treatment and aging resistance, weight reduction, radiation resistance, adjustment of immunity, treatment of Keshan disease, etc., and nutritional anticancer agent accepted by medical community. The organic tea leaves, after long term drinking, have better prevention and cure effect on hepatitis, arthritis, cataract, angiocardiopathy and hemorrhagic fever and other diseases and is benefit to health and longevity of the middle-aged and old.